LONDON, July 16, 2019 /PRNewswire/ -- ReNeuron Group plc
(AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, today announced that it has expanded its
intellectual property estate via the grant of a number of key
patents covering its exosome technology platform.
New patents have recently issued covering ReNeuron's neural stem
cell-derived exosomes and their methods of production. Patents
granted in China (CN 104321062 B and CN 104703609 B), Korea (KR 10-1993027), Japan (JP 6450673) and Europe (EP2833893 and EP2877187) include
claims to: (i) a method of producing exosomes derived from
differentiated stem cells; (ii) methods of production; and (iii)
composition of matter for exosomes derived from the Company's CTX
neural stem cells.
A further patent has issued in Japan (JP 6491661) with claims including use
of a neural stem cell exosome in the treatment of glioma (brain
cancer).
ReNeuron is targeting its exosome technology program towards
value-generating business partnerships in which its exosomes may be
exploited as a novel vector for delivering third party biological
drugs.
Following these patent grants, ReNeuron's patent estate consists
of over 40 patents worldwide covering its cell-based therapies and
exosome technology.
"We are pleased to have received these recent patent grants
relating to our exosome technology platform. We expect to
build this patent estate further in the near future," commented
Olav Hellebø, Chief Executive Officer of ReNeuron. "The recent
and expected grants will stand us in good stead as we seek valuable
collaboration deals to exploit ReNeuron's exosome platform as a
novel system for delivering advanced therapeutics such as gene
therapies."
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis
pigmentosa, and for disability as a result of stroke. ReNeuron is
also advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
View original
content:http://www.prnewswire.com/news-releases/reneuron-expands-exosome-ip-portfolio-with-key-patent-grants-300885525.html
SOURCE ReNeuron Group plc